Top 10 Performing Companies To Watch For 2015

Top 10 Performing Companies To Watch For 2015: Dynavax Technologies Corporation(DVAX)

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The company's lead product candidate includes HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide protection with fewer doses than current licensed vaccines. It also develops Universal Flu vaccine, a Phase 1b clinical trial vaccine for influenza prevention; SD-101, a Phase Ib clinical trial hepatitis C therapy; DV-601, a Phase Ib clinical trial hepatitis B therapy; AZD1419, a preclinical asthma therapy; and DV1179, a Phase 1 trial autoimmune and inflammatory disease therapy. Dynavax Technologies Corporation has strategic alliance with GlaxoSmithKline plc to discover, develop, and commercialize DV1179 and other endosomal toll-like receptor inhibitors for diseases, such as lupus, psoriasis, and rheumatoid arthritis; and develop a TLR8 inhibitor for the treatment of multiple autoimmune and i nflammatory diseases, as well as has research and license agreement with AstraZeneca to discover and develop TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was founded in 1996 and is based in Berkeley, California.

Advisors' Opinion:

• [By Selena Maranjian]

  Among holdings in which Farallon Capital Management increased its stake were Dynavax (NASDAQ: DVAX  ) and Freeport McMoRan Copper & Gold (NYSE: FCX  ) . Dynavax shares fell sharply upon an FDA rejection of its hepatitis B vaccine Heplisav. It may still win more limited approval, but Dynavax now has more work to do, and it's burning cash while its revenue has been shrinking. Fortunately, it does seem to have have ample cash to keep it afloat for a few years. Meanwhile, Dynavax has a new CEO, and its latest earnings report featured a loss slightly bigger than expe! cted.

• [By Keith Speights]

  Of course, developing a product for a market with great opportunity doesn't guarantee success for your investment strategy. An estimated 1 million people die each year from complications related to hepatitis B. Dynavax (NASDAQ: DVAX  ) developed a hep-B vaccine, Heplisav, that showed tremendous promise. However, safety concerns derailed approval for the drug. While Heplisav might still reach the market, Dynavax's experience highlights the risks even in a market with solid potential.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-10-performing-companies-to-watch-for-2015.html